High HCV cure rates in HIV coinfection cases at urban clinic

June 16, 2017

(HealthDay)—For patients in an urban clinic with hepatitis C virus (HCV) with HIV coinfection, HCV treatment is effective with standardized nurse/pharmacist support, according to a study published online June 13 in Hepatology.

Oluwaseun Falade-Nwulia, M.B.B.S., M.P.H., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined HCV treatment outcomes among 255 HCV coinfected patients (88 percent black) initiating direct-acting antivirals between February 2014 and March 2016 in an urban clinic. Patients received standardized HIV nurse/pharmacist support, which included telephone calls and nurse visits.

The researchers found that 60 percent of participants had significant fibrosis and 30 percent had received treatment for HCV. Ninety-one percent of patients received ledipasvir/sofosbuvir with or without ribavirin and received 12 weeks of treatment. The sustained virologic response rate was 97 percent, with no variation by race (black and non-black, 96 and 97 percent, respectively), history of drug use, alcohol use, or psychiatric diagnosis.

"HCV treatment was highly effective among HIV-infected patients who received care within an integrated / adherence support program," the authors write. "These results suggest that race and psychosocial comorbidity may not be barriers to HCV elimination."

Explore further: Investigational dose of oral interferon-free treatment can cure hepatitis C in children

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

SVR rates up with new regimens for HCV and HIV coinfection

February 24, 2015

(HealthDay)—For patients with hepatitis C virus (HCV) genotype 1 and HIV coinfection, new regimens are effective and correlate with high rates of sustained virologic response (SVR) after treatment, according to two studies ...

Pharmacist program can improve IFN-beta adherence in MS

May 17, 2017

(HealthDay)—A pharmacist medication adherence program can improve adherence to interferon-beta (IFN-β) among patients with relapsing-remitting multiple sclerosis (RRMS), according to a letter to the editor published online ...

Most patients prefer oral dual therapy in chronic hepatitis C

September 20, 2016

(HealthDay)—For patients with chronic hepatitis C (CHC), most prefer oral therapy with sofosbuvir (SOF) and ribavirin (RBV) versus triple therapy involving pegylated interferon (PegIFN), according to a study published online ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.